Revance Therapeutics Inc (RVNC)
2.925
-0.08
(-2.82%)
USD |
NASDAQ |
May 22, 16:00
2.925
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Free Cash Flow: -224.20M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -224.20M |
| December 31, 2023 | -223.46M |
| September 30, 2023 | -210.42M |
| June 30, 2023 | -213.83M |
| March 31, 2023 | -204.40M |
| December 31, 2022 | -196.76M |
| September 30, 2022 | -214.26M |
| June 30, 2022 | -206.05M |
| March 31, 2022 | -215.85M |
| December 31, 2021 | -231.91M |
| September 30, 2021 | -247.47M |
| June 30, 2021 | -253.26M |
| March 31, 2021 | -217.56M |
| December 31, 2020 | -182.72M |
| September 30, 2020 | -151.99M |
| June 30, 2020 | -128.96M |
| March 31, 2020 | -140.84M |
| December 31, 2019 | -109.39M |
| September 30, 2019 | -416.28M |
| June 30, 2019 | -411.28M |
| March 31, 2019 | -419.54M |
| Date | Value |
|---|---|
| December 31, 2018 | -419.26M |
| September 30, 2018 | -107.46M |
| June 30, 2018 | -101.01M |
| March 31, 2018 | -88.69M |
| December 31, 2017 | -97.97M |
| September 30, 2017 | -83.07M |
| June 30, 2017 | -75.58M |
| March 31, 2017 | -68.42M |
| December 31, 2016 | -63.30M |
| September 30, 2016 | -66.24M |
| June 30, 2016 | -66.00M |
| March 31, 2016 | -60.54M |
| December 31, 2015 | -59.00M |
| September 30, 2015 | -52.72M |
| June 30, 2015 | -53.17M |
| March 31, 2015 | -54.78M |
| December 31, 2014 | -62.05M |
| September 30, 2014 | -69.18M |
| June 30, 2014 | -61.29M |
| March 31, 2014 | -69.42M |
| December 31, 2013 | -54.24M |
Free Cash Flow Range, Past 5 Years
-416.28M
Minimum
Sep 2019
-109.39M
Maximum
Dec 2019
-220.04M
Average
-214.04M
Median
Free Cash Flow Benchmarks
| AbbVie Inc | 21.89B |
| Eli Lilly and Co | -3.896B |
| Aquestive Therapeutics Inc | -26.60M |
| Humacyte Inc | -83.53M |
| AN2 Therapeutics Inc | -59.28M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -65.94M |
| Cash from Investing (Quarterly) | -31.71M |
| Cash from Financing (Quarterly) | 92.83M |
| Free Cash Flow Per Share (Quarterly) | -0.7736 |
| Free Cash Flow to Equity (Quarterly) | -71.86M |
| Free Cash Flow Yield | -87.81% |